Shots:
- Senlang has granted Tempest an exclusive option to license its CD7-targeted lentiviral vector platform & in vivo CAR-T portfolio, incl. a BCMA/GPRC5D dual-targeting candidate for R/R MM & additional assets for hematologic malignancies & autoimmune diseases
- Senlang’s platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7+ T cells and NK cells, generating CAR-T & CAR-NK cells directly in pts without individualized cell collection or external manufacturing required
- The BCMA/GPRC5D dual-targeting candidate is being evaluated in an ongoing P-I dose-escalation study in R/R MM, while Tempest & Senlang will continue to assess the P-I results & broader portfolio during the option period
Ref: Globenewswire | Image: Senlang & Tempest | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
